JP2020529994A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529994A5
JP2020529994A5 JP2020505363A JP2020505363A JP2020529994A5 JP 2020529994 A5 JP2020529994 A5 JP 2020529994A5 JP 2020505363 A JP2020505363 A JP 2020505363A JP 2020505363 A JP2020505363 A JP 2020505363A JP 2020529994 A5 JP2020529994 A5 JP 2020529994A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044389 external-priority patent/WO2019027905A1/en
Publication of JP2020529994A publication Critical patent/JP2020529994A/ja
Publication of JP2020529994A5 publication Critical patent/JP2020529994A5/ja
Pending legal-status Critical Current

Links

JP2020505363A 2017-07-31 2018-07-30 有機リン酸誘導体 Pending JP2020529994A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762538879P 2017-07-31 2017-07-31
US62/538,879 2017-07-31
US201862637960P 2018-03-02 2018-03-02
US62/637,960 2018-03-02
PCT/US2018/044389 WO2019027905A1 (en) 2017-07-31 2018-07-30 ORGANOPHOSPHATE DERIVATIVES

Publications (2)

Publication Number Publication Date
JP2020529994A JP2020529994A (ja) 2020-10-15
JP2020529994A5 true JP2020529994A5 (enExample) 2021-09-09

Family

ID=65234161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505363A Pending JP2020529994A (ja) 2017-07-31 2018-07-30 有機リン酸誘導体

Country Status (7)

Country Link
US (1) US11306111B2 (enExample)
EP (1) EP3661513A4 (enExample)
JP (1) JP2020529994A (enExample)
CN (1) CN111491634A (enExample)
AU (1) AU2018312224A1 (enExample)
CA (1) CA3071612A1 (enExample)
WO (1) WO2019027905A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529994A (ja) 2017-07-31 2020-10-15 ジャニュアリー セラピューティクス,インク. 有機リン酸誘導体
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
SG11202008346PA (en) * 2018-03-02 2020-09-29 January Therapeutics Inc Nanoparticle compositions
US20210346507A1 (en) * 2018-08-20 2021-11-11 Cure Biopharma Inc. Gemcitabine prodrugs
CA3136954A1 (en) * 2019-04-22 2020-10-29 Ligand Pharmaceuticals Incorporated Cyclic phosphate compounds
GR1009958B (el) * 2019-04-24 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US11708637B2 (en) * 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
CN114365535A (zh) * 2019-09-10 2022-04-15 索尼集团公司 无线通信设备和方法
CN115768778A (zh) 2020-04-21 2023-03-07 配体药物公司 苄氧基磷酸(膦酸)酯化合物
EP4143199B1 (en) 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
EP4200301B1 (en) 2020-08-24 2025-02-26 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
JP2009504677A (ja) 2005-08-12 2009-02-05 メルク・エンド・カムパニー・インコーポレーテツド 新規2’−c−メチル及び4’−c−メチルヌクレオシド誘導体
WO2009126401A1 (en) 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
CN101732258B (zh) 2008-11-19 2013-12-25 复旦大学附属华山医院 一种用于肿瘤化疗的纳米微球制剂及其制备方法
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
KR20140005998A (ko) 2011-01-24 2014-01-15 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
US20130131008A1 (en) * 2011-10-25 2013-05-23 Board Of Regents, The University Of Texas System Lipophilic monophosphorylated derivatives and nanoparticles
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CN103239733A (zh) 2012-02-09 2013-08-14 复旦大学附属肿瘤医院 一种整合素靶向型载药白蛋白纳米粒制剂及其制备方法
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
EP4378461A3 (en) 2013-03-05 2024-09-11 The Regents of University of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8889701B1 (en) * 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
WO2015120237A2 (en) * 2014-02-06 2015-08-13 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
CN106459130A (zh) * 2014-03-03 2017-02-22 纽科利制药公司 吉西他滨类似物
CN117379452A (zh) 2014-06-24 2024-01-12 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
WO2016188943A1 (en) 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
CN104961786B (zh) 2015-06-05 2018-09-25 苏州大学 基于吉西他滨结构的前体药物及其应用
EP3399966B1 (en) 2016-01-08 2023-03-29 The Regents of the University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
JP2020529994A (ja) 2017-07-31 2020-10-15 ジャニュアリー セラピューティクス,インク. 有機リン酸誘導体
JP2021514985A (ja) 2018-03-02 2021-06-17 ジャニュアリー セラピューティクス,インク. ナノ粒子組成物
SG11202008346PA (en) 2018-03-02 2020-09-29 January Therapeutics Inc Nanoparticle compositions
WO2020041051A1 (en) 2018-08-20 2020-02-27 Cure Biopharma Inc. Gemcitabine prodrugs
US20210346507A1 (en) 2018-08-20 2021-11-11 Cure Biopharma Inc. Gemcitabine prodrugs
WO2020223530A1 (en) 2019-04-30 2020-11-05 Cure Biopharma Inc. Gemcitabine prodrugs
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support

Similar Documents

Publication Publication Date Title
JP2020529994A5 (enExample)
JP2020532547A5 (enExample)
JP2020532545A5 (enExample)
JP2020169171A5 (enExample)
JP2019524883A5 (enExample)
JP2016530259A5 (enExample)
JP2019526596A5 (enExample)
JP2014511891A5 (enExample)
JP2017523225A5 (enExample)
JP2019531279A5 (enExample)
JP2016106149A5 (enExample)
JP2017531038A5 (enExample)
JP2009504763A5 (enExample)
JP2013508279A5 (enExample)
JP2017517565A5 (enExample)
JP2020507589A5 (enExample)
JP2017537949A5 (enExample)
JP2012526728A5 (enExample)
JP2016534148A5 (enExample)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
JP2018533593A5 (enExample)
JP2011509309A5 (enExample)
JP2018502906A5 (enExample)
JP2016503797A5 (enExample)
JP2020511536A5 (enExample)